Related Experiment Video
Updated: Aug 27, 2025
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.4K
Urgent desensitization for severe amiodarone intolerance with a 12-step protocol
Christopher Purtell1, Mehek Mehta2, Ryan Steele2
1Section of Cardiovascular Electrophysiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Journal of Cardiovascular Electrophysiology
|September 23, 2022
Summary
A patient with severe heart condition and electrical storm successfully underwent rapid amiodarone desensitization after an allergic reaction. This treatment controlled arrhythmias without adverse effects, offering a new therapeutic option.
Area of Science:
- Cardiology
- Pharmacology
- Allergy and Immunology
Background:
- Severe nonischemic cardiomyopathy can lead to life-threatening cardiogenic shock and electrical storm.
- Electrical storm refractory to standard antiarrhythmic therapies presents a significant clinical challenge.
- Amiodarone is a critical antiarrhythmic agent, but hypersensitivity reactions can limit its use.
Observation:
- A 68-year-old male patient with severe nonischemic cardiomyopathy experienced refractory electrical storm.
- The patient had a history of severe skin reaction to amiodarone, precluding its standard use.
- Alternative antiarrhythmic agents were ineffective in managing the electrical storm.
Findings:
- An emergent amiodarone desensitization protocol was initiated.
- The patient successfully tolerated amiodarone within 12 hours of initiating the desensitization protocol.
- Amiodarone effectively suppressed the electrical storm without recurrence of allergic reactions or hemodynamic compromise.
Implications:
- Rapid desensitization is a viable strategy for patients requiring amiodarone despite prior hypersensitivity.
- This approach may expand treatment options for refractory electrical storm in cardiomyopathy.
- Further research into desensitization protocols for amiodarone-induced hypersensitivity is warranted.
Related Concept Videos
01:20Desensitization and Tachyphylaxis
2.1K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.1K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
65
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
65
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
826
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
826
01:19Depolarizing Blockers: Pharmocokinetics
372
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
372